Literature DB >> 21263135

Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies.

S I van Nes1, E K Vanhoutte, P A van Doorn, M Hermans, M Bakkers, K Kuitwaard, C G Faber, I S J Merkies.   

Abstract

OBJECTIVE: To develop a patient-based, linearly weighted scale that captures activity and social participation limitations in patients with Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and gammopathy-related polyneuropathy (MGUSP).
METHODS: A preliminary Rasch-built Overall Disability Scale (R-ODS) containing 146 activity and participation items was constructed, based on the WHO International Classification of Functioning, Disability and Health, literature search, and patient interviews. The preliminary R-ODS was assessed twice (interval: 2-4 weeks; test-retest reliability studies) in 294 patients who experienced GBS in the past (n = 174) or currently have stable CIDP (n = 80) or MGUSP (n = 40). Data were analyzed using the Rasch unidimensional measurement model (RUMM2020).
RESULTS: The preliminary R-ODS did not meet the Rasch model expectations. Based on disordered thresholds, misfit statistics, item bias, and local dependency, items were systematically removed to improve the model fit, regularly controlling the class intervals and model statistics. Finally, we succeeded in constructing a 24-item scale that fulfilled all Rasch requirements. "Reading a newspaper/book" and "eating" were the 2 easiest items; "standing for hours" and "running" were the most difficult ones. Good validity and reliability were obtained.
CONCLUSION: The R-ODS is a linearly weighted scale that specifically captures activity and social participation limitations in patients with GBS, CIDP, and MGUSP. Compared to the Overall Disability Sum Score, the R-ODS represents a wider range of item difficulties, thereby better targeting patients with different ability levels. If responsive, the R-ODS will be valuable for future clinical trials and follow-up studies in these conditions.

Entities:  

Mesh:

Year:  2011        PMID: 21263135     DOI: 10.1212/WNL.0b013e318208824b

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  63 in total

Review 1.  Progress in inflammatory neuropathy -the legacy of Dr Jack Griffin.

Authors:  Eva L Feldman; Richard A C Hughes; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2015-10-13       Impact factor: 42.937

Review 2.  Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard Ac Hughes; Man Mohan Mehndiratta; Yusuf A Rajabally
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

Review 3.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

Review 4.  The pathogenesis of multifocal motor neuropathy and an update on current management options.

Authors:  Jean-Marc Léger; Raquel Guimarães-Costa; Ruxandra Iancu Ferfoglia
Journal:  Ther Adv Neurol Disord       Date:  2015-05       Impact factor: 6.570

5.  Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.

Authors:  Ellen M Lavoie Smith; Noah Zanville; Grace Kanzawa-Lee; Clare Donohoe; Celia Bridges; Charles Loprinzi; Jennifer Le-Rademacher; James J Yang
Journal:  Support Care Cancer       Date:  2018-11-20       Impact factor: 3.603

6.  Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study.

Authors:  Dario Cocito; Aristide Merola; Erdita Peci; Anna Mazzeo; Raffaella Fazio; Ada Francia; Paola Valentino; Rocco Liguori; Massimiliano Filosto; Gabriele Siciliano; Angelo Maurizio Clerici; Stefania Lelli; Girolama Alessandra Marfia; Giovanni Antonini; Ilaria Cecconi; Eduardo Nobile-Orazio; Leonardo Lopiano
Journal:  J Neurol       Date:  2014-08-23       Impact factor: 4.849

Review 7.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

Review 8.  Corticosteroids for Guillain-Barré syndrome.

Authors:  Richard Ac Hughes; Ruth Brassington; Angela A Gunn; Pieter A van Doorn
Journal:  Cochrane Database Syst Rev       Date:  2016-10-24

9.  Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability.

Authors:  Joshua Burns; Robert Ouvrier; Tim Estilow; Rosemary Shy; Matilde Laurá; Julie F Pallant; Monkol Lek; Francesco Muntoni; Mary M Reilly; Davide Pareyson; Gyula Acsadi; Michael E Shy; Richard S Finkel
Journal:  Ann Neurol       Date:  2012-05       Impact factor: 10.422

10.  Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens?

Authors:  Yusuf A Rajabally; Siew L Wong; David A Kearney
Journal:  J Neurol       Date:  2013-05-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.